December 01, 2020

IBRI RESEARCH PUBLISHED: Persistent or Transient Human ß Cell Dysfunction Induced by Metabolic Stress: Specific Signatures and Shared Gene Expression with Type 2 Diabetes

Abstract Pancreatic β cell failure is key to type 2 diabetes (T2D) onset and progression. Here, we assess whether human β cell dysfunction induced by metabolic stress is reversible,...

November 28, 2020

IBRI RESEARCH PUBLISHED: Phenotypic Sexual Dimorphism in Response to Dietary Fat Manipulation in C57BL/6J Mice

Abstract Background : Obesity and the metabolic syndrome are increasingly prevalent in society and their complications and response to treatment exhibit sexual dimorphism. Mouse models of high fat diet-induced...

November 20, 2020

IBRI RESEARCH PUBLISHED: Integration of single-cell datasets reveals novel transcriptomic signatures of ß-cells in human T2D

Abstract Pancreatic islet β-cell failure is key to the onset and progression of type 2 diabetes (T2D). The advent of single-cell RNA sequencing (scRNA-seq) has opened the possibility to...

November 16, 2020

IBRI RESEARCH PUBLISHED: Enzyme Immunoassay-Based Platform for Accurate Detection of Serum Pathological a-Synuclein in Parkinson’s Disease Patients

Abstract An assay for accurately diagnosing early stage Parkinson’s Disease (PD) is currently unavailable, and therefore, there is an urgent and unmet need. Such a diagnostic assay will enable...

November 12, 2020

IBRI IN THE NEWS: Biosciences Research Institute Adds Board Members

The Indiana Biosciences Research Institute has added eight members to its board of directors, including Bob Bernhard (pictured) and Wendy Srnic (pictured). Bernhard serves as vice president for research at...

November 11, 2020

IBRI RESEARCH PUBLISHED: YIPF5 Mutations Cause Neonatal Diabetes and Microcephaly through Endoplasmic Reticulum Stress

Abstract Neonatal diabetes is caused by single gene mutations reducing pancreatic β cell number or impairing β cell function. Understanding the genetic basis of rare diabetes subtypes highlights fundamental...

November 09, 2020

Indiana Biosciences Research Institute Names New Board Members

Indianapolis, Ind. – The Indiana Biosciences Research Institute (IBRI), a leading industry-inspired applied research institute, is pleased to announce the addition of eight members to its Board of Directors. Its...

November 02, 2020

IBRI IN THE NEWS: The Dialogue of Diabetes

Over the past 60 years, the incidence of type I diabetes in parts of the word has increased sixfold, and we don’t know why. In the Eizirik Lab at the...

October 26, 2020

IBRI RESEARCH PUBLISHED: Utilization of Electronic Health Records for the Assessment of Adiponectin Receptor Autoantibodies during the Progression of Cardio-metabolic Comorbidities

Abstact Background : Diabetes is a complex, multi-symptomatic disease whose complications drives increases in healthcare costs as the diabetes prevalence grows rapidly world-wide. Real-world electronic health records (EHRs) coupled...

October 20, 2020

IBRI RESEARCH PUBLISHED: SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic ß-cells and in the human pancreas microvasculature

Abstract Increasing evidence demonstrated that the expression of Angiotensin I-Converting Enzyme type 2 (ACE2), is a necessary step for SARS-CoV-2 infection permissiveness. In the light of the recent data...

First 1 2 3 4 5  ... Last 
2020 Annual Report cover

The IBRI 2020 Annual Report is now available. The report theme, ‘Shaping the Future of Translational Science,’ reflects the IBRI’s commitment to turning scientific discovery into improved outcomes for patients.